The ENPP1 Prospective Observational Study is designed to look at how ENPP1 Deficiency presents and progresses from birth through adulthood. The study will include people across all age groups.
Researchers will follow participants over time to:
Participation in this study could help scientists create an effective treatment for ENPP1 Deficiency.
Individuals who meet the eligibility criteria for the testing program can receive a no-cost, third-party genetic test to determine if they have the condition or are a carrier for ENPP1 Deficiency. Those with confirmed ENPP1 status may be eligible to participate in studies to help researchers better understand and treat the condition, including the ENPP1 Deficiency Prospective Observational Study previously mentioned.
Your HCP will order your test by following the instructions.
For more information, including FAQs:
©2021 Inozyme Pharma. All Rights Reserved.
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton that can be life-threatening and debilitating.